Skip to main navigation Skip to search Skip to main content

Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models

  • SUNY Buffalo

Research output: Contribution to journalArticlepeer-review

83 Scopus citations

Abstract

Target-mediated drug disposition (TMDD) models have been applied to describe the pharmacokinetics of drugs whose distribution and/or clearance are affected by its target due to high binding affinity and limited capacity. The Michaelis-Menten (M-M) model has also been frequently used to describe the pharmacokinetics of such drugs. The purpose of this study is to investigate conditions for equivalence between M-M and TMDD pharmacokinetic models and provide guidelines for selection between these two approaches. Theoretical derivations were used to determine conditions under which M-M and TMDD pharmacokinetic models are equivalent. Computer simulations and model fitting were conducted to demonstrate these conditions. Typical M-M and TMDD profiles were simulated based on literature data for an anti-CD4 monoclonal antibody (TRX1) and phenytoin administered intravenously. Both models were fitted to data and goodness of fit criteria were evaluated for model selection. A case study of recombinant human erythropoietin was conducted to qualify results. A rapid binding TMDD model is equivalent to the M-M model if total target density R tot is constant, and R tot K D /(K D + C) 2 1 where K D represents the dissociation constant and C is the free drug concentration. Under these conditions, M-M parameters are defined as: V max = k int R tot V c and K m = K D where k int represents an internalization rate constant, and V c is the volume of the central compartment. R tot is constant if and only if k int = k deg, where k deg is a degradation rate constant. If the TMDD model predictions are not sensitive to k int or k deg parameters, the condition of R tot K D /(K D + C) 2 1 alone can preserve the equivalence between rapid binding TMDD and M-M models. The model selection process for drugs that exhibit TMDD should involve a full mechanistic model as well as reduced models. The best model should adequately describe the data and have a minimal set of parameters estimated with acceptable precision.

Original languageEnglish
Pages (from-to)25-47
Number of pages23
JournalJournal of Pharmacokinetics and Pharmacodynamics
Volume37
Issue number1
DOIs
StatePublished - Feb 2010

Keywords

  • Erythropoietin
  • Michaels-Menten
  • Nonlinear pharmacokinetics
  • Target-mediated drug disposition

Fingerprint

Dive into the research topics of 'Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models'. Together they form a unique fingerprint.

Cite this